The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.
Enzalutamide Plus ADT Improves rPFS, OS in Metastatic HSPC With Prior ADTSeptember 20th 2022
Enzalutamide plus androgen deprivation therapy elicited significant improvements in radiographic progression-free survival and overall survival vs placebo in patients with metastatic hormone-sensitive prostate cancer.
PSA Decline After Lutetium Lu 177 Vipivotide Tetraxetan Treatment Prolongs Survival in PSMA-Positive mCRPC
The decline of prostate-specific antigen following treatment with lutetium Lu 177 vipivotide tetraxetan plus standard of care was linked with prolonged radiographic progression-free survival and overall survival in patients with progressive prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.
Pembrolizumab/Olaparib Combo Fails to Improve rPFS, OS Vs Novel Hormonal Agents in mCRPCSeptember 12th 2022
The combination of pembrolizumab and olaparib did not significantly improve radiographic progression-free survival and overall survival compared with novel hormonal agents in patients with molecularly unselected, previously treated metastatic castration-resistant prostate cancer.
Two Years Post-operative ADT Plus Radiotherapy Improves MFS, Time to Salvage Therapy in Prostate CancerSeptember 12th 2022
The addition of 24 months of androgen deprivation therapy to postoperative radiotherapy after radical prostatectomy provided a metastasis-free survival benefit and improved time to salvage therapy in patients with prostate cancer.
Olaparib/Abiraterone Continues to Provide Superior Clinical Benefit Over Abiraterone Alone in Frontline mCRPCSeptember 11th 2022
The combination of olaparib plus abiraterone acetate and prednisone or prednisolone demonstrated a continuing trend toward an overall survival benefit when used in the first-line treatment of patients with metastatic castration-resistant prostate cancer.
Addition of Enzalutamide to Abiraterone/Prednisolone Deemed Unnecessary in Metastatic HSPCSeptember 11th 2022
Although the combination of androgen deprivation therapy, abiraterone acetate, and prednisolone showed a clinically meaningful 7-year improvement in overall survival, AAP plus enzalutamide is not recommended in patients with metastatic hormone-sensitive prostate cancer.
Pembrolizumab Plus Abiraterone/Prednisone Shows Sustained Efficacy in Chemotherapy-Naïve mCRPCSeptember 10th 2022
Pembrolizumab plus abiraterone acetate and prednisone demonstrated continued efficacy and tolerability in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.
AI-Powered Focal Therapy Maps Future Treatment Paradigm in Prostate Cancer
For clinicians tasked with treating patients with prostate cancer, disease visualization has traditionally consisted of imprecise techniques such as MRI. However, a new artificial intelligence-based approach by Avenda Health is poised to potentially revolutionize the treatment landscape in the field.
FDA Grants Priority Review to Olaparib/Abiraterone Regimen in Metastatic Castration-Resistant Prostate CancerAugust 16th 2022
The FDA has granted priority review to a supplemental new drug application seeking the approval of olaparib in combination with abiraterone acetate and prednisone or prednisolone in adult patients with metastatic castration-resistant prostate cancer.
Dr. Katz on Neoadjuvant mFOLFIRINOX in Pancreatic CancerAugust 11th 2022
Matthew H. G. Katz, MD, CMQ, FACS, FASCO, discusses the efficacy of mFOLFIRINOX, a chemotherapy regimen consisting of oxaliplatin, irinotecan, leucovorin, and fluorouracil, prior to pancreatectomy in patients with borderline resectable pancreatic cancer.
New Cancer Study Results Confirm Lasting Effects on 9/11 First RespondersAugust 5th 2022
Research investigating the physical and mental health consequences of being at the World Trade Center site during and after the terrorist attacks has been instrumental in obtaining health care coverage for thousands of individuals.
REGN5678 Plus Cemiplimab Demonstrates Early Activity in mCRPCAugust 3rd 2022
The novel PSMAxCD38 costimulatory bispecific antibody REGN5678 has shown encouraging efficacy in combination with cemiplimab in patients with advanced metastatic castration-resistant prostate cancer, according to preliminary findings from an ongoing phase 1/2 trial (NCT03972657).
Pembrolizumab Plus Chemotherapy Fails to Improve OS, Radiographic PFS in mCRPCAugust 3rd 2022
Pembrolizumab plus docetaxel failed to elicit a statistically significant improvement in overall survival and radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer, missing the coprimary end points of the phase 3 KEYNOTE-921 trial.
Retrospective Analysis Highlights Disparities in Germline Testing in Prostate CancerAugust 2nd 2022
Carrie Horton, MS, CGC, discusses how the findings from a retrospective analysis of germline testing rates among racially diverse groups of men with prostate cancer will guide future research and influence the steps community oncologists can take to increase testing rates.
SHR3680 Plus ADT Improves Survival Vs Bicalutamide/ADT in High-Volume mHSPC
The addition of SHR3680 to androgen deprivation therapy significantly improved radiographic progression-free survival and overall survival compared with bicalutamide plus ADT in patients with high-volume, metastatic hormone-sensitive prostate cancer, according to data from the phase 3 CHART trial.